BridgeBio Pharma (NASDAQ:BBIO) Shares Purchased by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on November 2nd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Stock Performance

Shares of BBIO traded down $1.37 on Thursday, hitting $78.17. 1,804,089 shares of the stock traded hands, compared to its average volume of 2,911,446. The company has a market capitalization of $15.23 billion, a PE ratio of -25.71 and a beta of 0.97. The business has a 50 day simple moving average of $69.92 and a 200 day simple moving average of $72.79. BridgeBio Pharma, Inc. has a one year low of $62.50 and a one year high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12. The business had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. The business’s revenue was up 192.6% compared to the same quarter last year. During the same period last year, the company posted ($0.95) earnings per share. On average, equities analysts expect that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors and hedge funds have recently modified their holdings of BBIO. Silvant Capital Management LLC purchased a new stake in BridgeBio Pharma during the second quarter valued at $28,000. Allworth Financial LP bought a new position in BridgeBio Pharma in the second quarter valued at about $31,000. Root Financial Partners LLC purchased a new position in BridgeBio Pharma in the third quarter worth about $28,000. SBI Securities Co. Ltd. boosted its position in BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock worth $29,000 after purchasing an additional 157 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in BridgeBio Pharma in the second quarter worth about $44,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group upped their price target on BridgeBio Pharma from $106.00 to $108.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Wells Fargo & Company lifted their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Barclays decreased their target price on BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Morgan Stanley upped their target price on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Weiss Ratings downgraded shares of BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, September 25th. Nineteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.26.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer owned 495,686 shares in the company, valued at $34,241,988.88. This represents a 1.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. The trade was a 1.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 56,980 shares of company stock valued at $4,563,699. Corporate insiders own 14.23% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.